These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 34281850)
1. Lactate Dehydrogenase Is a Serum Prognostic Factor in Clinically Regional Lymph Node-positive Prostate Cancer. Blas L; Shiota M; Yamada S; Ieiri K; Nagakawa S; Tsukahara S; Matsumoto T; Kashiwagi E; Takeuchi A; Inokuchi J; Shiga KI; Yokomizo A; Eto M Anticancer Res; 2021 Aug; 41(8):3885-3889. PubMed ID: 34281850 [TBL] [Abstract][Full Text] [Related]
2. Serum Prognostic Factors of Androgen-deprivation Therapy Among Japanese Men With Kobayashi T; Namitome R; Hirata YU; Shiota M; Imada K; Kashiwagi E; Takeuchi A; Inokuchi J; Tatsugami K; Eto M Anticancer Res; 2019 Jun; 39(6):3191-3195. PubMed ID: 31177166 [TBL] [Abstract][Full Text] [Related]
3. Prognostic Value of Lactate Dehydrogenase in Metastatic Prostate Cancer: A Systematic Review and Meta-analysis. Mori K; Kimura S; Parizi MK; Enikeev DV; Glybochko PV; Seebacher V; Fajkovic H; Mostafaei H; Lysenko I; Janisch F; Egawa S; Shariat SF Clin Genitourin Cancer; 2019 Dec; 17(6):409-418. PubMed ID: 31558410 [TBL] [Abstract][Full Text] [Related]
4. Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model. Gravis G; Boher JM; Fizazi K; Joly F; Priou F; Marino P; Latorzeff I; Delva R; Krakowski I; Laguerre B; Walz J; Rolland F; Théodore C; Deplanque G; Ferrero JM; Pouessel D; Mourey L; Beuzeboc P; Zanetta S; Habibian M; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Labourey JL; Machiels JP; El Kouri C; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Soulie M; Oudard S Eur Urol; 2015 Aug; 68(2):196-204. PubMed ID: 25277272 [TBL] [Abstract][Full Text] [Related]
5. Prognostic Value of Lower Tract Urinary Symptoms in Clinically Regional Lymph Node-positive Prostate Cancer. Blas L; Ieiri K; Shiota M; Nagakawa S; Tsukahara S; Matsumoto T; Kashiwagi E; Takeuchi A; Inokuchi J; Shiga KI; Yokomizo A; Eto M Anticancer Res; 2021 Nov; 41(11):5593-5598. PubMed ID: 34732430 [TBL] [Abstract][Full Text] [Related]
6. The prognosis and the impact of radiotherapy in clinically regional lymph node-positive prostate cancer: Which patients are candidates for local therapy with radiation? Ieiri K; Shiota M; Kashiwagi E; Takeuchi A; Takahashi R; Inokuchi J; Iwai H; Shiga KI; Yokomizo A; Yoshitake T; Shioyama Y; Ishigami K; Terashima H; Eto M Urol Oncol; 2020 Dec; 38(12):931.e1-931.e7. PubMed ID: 32900626 [TBL] [Abstract][Full Text] [Related]
7. Whole pelvis radiotherapy for pathological node-positive prostate cancer : Oncological outcome and prognostic factors. Poelaert F; Fonteyne V; Ost P; De Troyer B; Decaestecker K; De Meerleer G; De Visschere P; Claeys T; Dhondt B; Lumen N Strahlenther Onkol; 2017 Jun; 193(6):444-451. PubMed ID: 28101585 [TBL] [Abstract][Full Text] [Related]
8. Racial disparity in clinical course and outcome of metastatic androgen-independent prostate cancer. Thatai LC; Banerjee M; Lai Z; Vaishampayan U Urology; 2004 Oct; 64(4):738-43. PubMed ID: 15491712 [TBL] [Abstract][Full Text] [Related]
9. Pretreatment serum lactate dehydrogenase is an independent prognostic factor for patients receiving neoadjuvant chemotherapy for locally advanced cervical cancer. Li J; Wu MF; Lu HW; Chen Q; Lin ZQ; Wang LJ Cancer Med; 2016 Aug; 5(8):1863-72. PubMed ID: 27350066 [TBL] [Abstract][Full Text] [Related]
10. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients. Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093 [TBL] [Abstract][Full Text] [Related]
11. Comparison of different lymph node staging schemes in prostate cancer patients with lymph node metastasis. Jin S; Wang J; Shen Y; Gan H; Xu P; Wei Y; Wei J; Wu J; Wang B; Wang J; Yang C; Zhu Y; Ye D Int Urol Nephrol; 2020 Jan; 52(1):87-95. PubMed ID: 31552575 [TBL] [Abstract][Full Text] [Related]
13. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level. Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789 [TBL] [Abstract][Full Text] [Related]
14. Risk of prostate carcinoma death in patients with lymph node metastasis. Cheng L; Zincke H; Blute ML; Bergstralh EJ; Scherer B; Bostwick DG Cancer; 2001 Jan; 91(1):66-73. PubMed ID: 11148561 [TBL] [Abstract][Full Text] [Related]
15. Prognostic value of combined preoperative lactate dehydrogenase and alkaline phosphatase levels in patients with resectable pancreatic ductal adenocarcinoma. Ji F; Fu SJ; Guo ZY; Pang H; Ju WQ; Wang DP; Hua YP; He XS Medicine (Baltimore); 2016 Jul; 95(27):e4065. PubMed ID: 27399091 [TBL] [Abstract][Full Text] [Related]
16. Prognostic Significance of Lactate Dehydrogenase in Patients Undergoing Surgical Resection for Laryngeal Squamous Cell Carcinoma. Guo E; Guo L; An C; Zhang C; Song K; Wang G; Duan C; Zhang X; Yang X; Yuan Z; Guo J; Sun J; Meng H; Chang R; Li X; Xiu C; Mao X; Miao S Cancer Control; 2020; 27(1):1073274820978795. PubMed ID: 33297727 [TBL] [Abstract][Full Text] [Related]
17. Lactate dehydrogenase is a prognostic indicator for prostate cancer patients with bone metastasis. Naruse K; Yamada Y; Aoki S; Taki T; Nakamura K; Tobiume M; Zennami K; Katsuda R; Sai S; Nishio Y; Inoue Y; Noguchi H; Hondai N Hinyokika Kiyo; 2007 May; 53(5):287-92. PubMed ID: 17561711 [TBL] [Abstract][Full Text] [Related]
18. Comparison of Hematologic and Other Prognostic Markers in Metastatic Colorectal Cancer. Mercier J; Voutsadakis IA J Gastrointest Cancer; 2019 Sep; 50(3):493-506. PubMed ID: 29704170 [TBL] [Abstract][Full Text] [Related]
19. Contribution of Serum Biomarkers to Prognostic Assessment in Patients With Oligometastatic Prostate Cancer. Nieder C; Dalhaug A; Pawinski A In Vivo; 2019; 33(2):465-468. PubMed ID: 30804126 [TBL] [Abstract][Full Text] [Related]